Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.

Fiche publication

Date publication

juin 2025

Journal

BMJ oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Earl HM, Hiller L, Dunn JA, Patel M, Conte P, D'Amico R, Guarneri V, Joensuu H, Huttunen T, Hatzidaki D, Georgoulias V, Abraham JE, Miles D, Cameron DA, Wardley AM, Pivot X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40552247

Résumé

Adjuvant trastuzumab in combination with chemotherapy has significantly improved survival in patients with HER2-positive early breast cancer but, since introduction in 2005, the 12 months duration has been questioned and trials have tested shorter durations.